In a report released today, Eric Joseph from J.P. Morgan maintained a Hold rating on Aligos Therapeutics (ALGS – Research Report), with a price target of $5.00. The company’s shares closed last Wednesday at $1.24, close to its 52-week low of $1.16.
According to TipRanks.com, Joseph is a 1-star analyst with an average return of -3.7% and a 44.2% success rate. Joseph covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Karyopharm Therapeutics, and Enanta Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Aligos Therapeutics with a $7.33 average price target, implying a 495.9% upside from current levels. In a report released today, SVB Securities also downgraded the stock to Hold with a $3.00 price target.
See the top stocks recommended by analysts >>
Aligos Therapeutics’ market cap is currently $52.94M and has a P/E ratio of -0.39.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).
Read More on ALGS:
